Teva seeks to launch generic Truvada, Gilead says

11/17/2008 | Reuters · TheStreet.com

Gilead Sciences said it was notified that Teva Pharmaceutical Industries filed for FDA approval to market a copy of Truvada, an HIV treatment combining Gilead's drugs Viread and Emtriva. Gilead, which has 45 days to file a patent-infringement suit against Teva, said 10 patents need to expire or be nullified before a generic version of Truvada can be launched.

View Full Article in:

Reuters · TheStreet.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC